TRAW
Traws Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TRAW
Traws Pharma, Inc.
A clinical-stage biopharmaceutical company that developing novel drugs for cancer
12 Penns Trail, Newtown, PA 18940
--
Traws Pharma, Inc., incorporated in Delaware on December 22, 1998 and commenced operations on January 1, 1999, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule drug candidates for the treatment of cancer. Traws is developing next-generation, best-in-class antiviral drugs for influenza, COVID and other respiratory infections, as well as narazaciclib for oncology.
Earnings Call
Q2/2025
Estimate EPS--
Actual EPS-0.16
Estimate Revenue--
Actual Revenue2.73M
Traws Pharma's Q2 2025 Earnings Call: Unraveling Contradictions in Narazaciclib Trials and Future Prospects
Aug 14,2025 01:23
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TRAW has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -9.16, beating expectations. The chart below visualizes how TRAW has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
